Parkinsons disease: a disorder due to nigral glutathione deficiency?

DOI: 10.1016/0304-3940(82)90390-1
Neuroscience Letters, 1982, 33, 305-10.

#	Paper	IF	Citations
699	Aetiology of Parkinson's disease. **1983**, 2, 1457-9		361
698	Etiology of Parkinson's disease: A research strategy. **1984**, 11, 24-8		96
697	Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. **1984**, 43, 990-3		127
696	The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. **1984**, 33, 2697-8		45
695	The free radical theory of aging: A critical review. **1985**, 1, 165-223		66
694	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig. **1985**, 36, 1233-8		35
693	In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. *Neuroscience Letters*, **1985**, 59, 9-14	3.3	29
692	Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid. **1985**, 24, 1257-9		56
691	Glutathione peroxidase activity in Parkinson's disease brain. *Neuroscience Letters*, **1985**, 58, 343-6	3.3	265
690	Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum. **1985**, 113, 135-6		38
689	Glutathione-induced inhibition of Na+-independent and -dependent bindings of L-[3H]glutamate in rat brain. **1986**, 39, 2411-8		75
688	Lipid peroxidation as cause of nigral cell death in Parkinson's disease. **1986**, 2, 639-40		136
687	The potential use of vitamin E and selenium in parkinsonism. **1986**, 20, 87-94		26
686	Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. *Neuroscience Letters*, **1986**, 63, 56-60	3.3	122
685	Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. *Neuroscience Letters*, **1986**, 67, 269-74	3.3	315
684	Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. *Neuroscience Letters*, **1986**, 70, 261-5	3.3	30
683	Effect of nicotine and amphetamine on the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. **1986**, 25, 1231-4		14

682	Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. **1986**, 25, 1071-4		58
681	In vivo voltammetry: some methodological considerations. **1986**, 17, 1-29		64
680	Brain glutathione peroxidase in neurodegenerative disorders. **1986**, 4, 23-8		48
679	Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism. **1987**, 35, 660-8		4
678	Raised cerebrospinal-fluid copper concentration in Parkinson's disease. **1987**, 2, 238-41		168
677	Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. **1987**, 81, 321-31		45
676	Reduced concentrations of ascorbic acid and glutathione in a single case of Rett syndrome: a postmortem brain study. **1987**, 9, 529-31		21
675	COMMUNICATION. **1987**, 92, 511P-792p		1
674	Reduced and oxidized glutathione in human and monkey brain. *Neuroscience Letters*, **1987**, 74, 112-8	3.3	149
673	Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. *Neuroscience Letters*, **1987**, 74, 217-20	3.3	25
672	Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. **1987**, 2, 241-4		33
671	Possible presence of [3H]glutathione (GSH) binding sites in synaptic membranes from rat brain. **1987**, 4, 486-96		33
670	Possible presence of [3H]glutathione (GSH) binding sites in synaptic membranes from rat brain. **1987**, 4, 486-496		
669	Erythrocyte antioxidant activity in human patients with Parkinson's disease. *Neuroscience Letters*, **1987**, 75, 345-8	3.3	31
668	MPTP induced dopaminergic neurotoxicity-a useful model in the study of parkinson's disease?. **1987**, 11, 379-81		9
667	Antioxidant therapy in Parkinson's disease. **1987**, 14, 483-7		30
666	Effects of manganese oxide on monkeys as revealed by a combined neurochemical, histological and neurophysiological evaluation. **1987**, 61, 46-52		119
665	Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. **1987**, 21, 331-6		106

664	Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. **1988**, 8, 285-91		37
663	Pyridine and other coal tar constituents as free radical-generating environmental neurotoxicants. **1988**, 84, 217-22		15
662	Covalent protein binding of a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mouse and monkey brain in vitro and in vivo. **1988**, 37, 4163-9		4
661	Regional distribution of malonaldehyde in mouse brain. **1988**, 37, 2287-8		15
660	Temperature-dependent and -independent apparent binding activities of [3H]glutathione in brain synaptic membranes. **1988**, 463, 37-46		29
659	Role of dopamine in manganese neurotoxicity. **1988**, 473, 236-40		68
658	Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. **1988**, 86, 321-31		219
657	2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease. **1988**, 85, 309-17		10
656	Prevention of progression of Parkinson's disease with antioxidative therapy. **1988**, 12, 165-72		11
655	Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease. *Neuroscience Letters*, **1988**, 87, 307-10	3.3	48
654	Susceptibility in Parkinson's disease. 'Of mice and men'. **1988**, 27, 205-7		2
653	The Neurobiology of N-Acetylasparty. **1988**, 39-100		67
652	DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. **1989**, 46, 1052-60		345
651	Clues to the mechanism underlying dopamine cell death in Parkinson's disease. **1989**, Suppl, 22-8		40
650	Interactions of manganese with human brain glutathione-S-transferase. **1989**, 57, 183-91		19
649	The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. **1989**, 1, 279-95		136
648	Neurochemical perspectives to the function of monoamine oxidase. *Acta Neurologica Scandinavica*, **1989**, 126, 41-5	3.8	48
647	Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. **1989**, 52, 381-9		1168

646	Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. **1989**, 52, 515-20		1208
645	A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. **1989**, 53, 692-7		412
644	Low glutathione levels in brain regions of aged rats. *Neuroscience Letters*, **1989**, 101, 187-90	3.3	84
643	The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness. **1989**, 570, 186-96		57
642	Retrospective Evaluation of Vitamin E Therapy in Parkinson's Disease. **1989**, 570, 441-442		4
641	The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. **1989** , 190, 399-402		77
640	Selective potentiation by L-cysteine of apparent binding activity of [3H]glutathione in synaptic membranes of rat brain. **1989**, 38, 1499-505		13
639	Xenobiotic metabolism in human brain--presence of cytochrome P-450 and associated mono-oxygenases. **1989**, 496, 331-5		73
638	Administration of L-2-oxothiazolidine-4-carboxylate increases glutathione levels in rat brain. **1989**, 478, 181-3		48
637	Chemically induced Parkinson's disease. II: Intermediates in the oxidation and reduction reactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium ion and its deprotonated form. **1989**, 158, 63-71		14
636	The role of environmental toxins in the etiology of Parkinson's disease. **1989**, 12, 49-54		236
635	Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. **1989**, 31, 1-79		155
634	7 Free Radicals, Central Nervous System Processes and Brain Functions. **1990**, 172-192		1
633	The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. **1990**, 22, 291-332		49
632	The glutathionyl radical formation in the reaction between manganese and glutathione and its neurotoxic implications. **1990**, 33, 83-7		14
631	Parkinson's disease: management. **1991**, 337, 1324-7		21
630	Influence of aging on the acute depletion of reduced glutathione induced by electrophilic agents. **1991**, 12, 227-31		9
629	Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. **1991**, 1, 228-48		50

628	Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain?. **1991**, 41, 1099-105		84
627	Parkinson's disease: pathophysiology. **1991**, 337, 1321-4		382
626	Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice. **1991**, 22, 669-72		14
625	Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. **1991**, 114 (Pt 4), 1953-75		845
624	Environment, genetics and idiopathic Parkinson's disease. **1991**, 18, 70-6		18
623	MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease. **1991** , 18, 77-82		12
622	Selegiline in the treatment of Parkinson's disease. **1991**, 302, 392-5		3
621	Comparison of effects of Aroclors 1016 and 1260 on non-human primate catecholamine function. **1991**, 66, 145-63		110
620	Cellular and regional distribution of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-phthaldialdehyde-induced histofluorescence. **1991**, 107, 215-27		111
619	Oxygen free radicals and Parkinson's disease. **1991**, 10, 161-9		250
618	Determination of glutathione, glutathione disulphide, ascorbic acid and dehydroascorbic acid in tissues by reversed-phase liquid chromatography with electrochemical detection. **1991**, 339, 258-260		13
617	Oxidative stress as a cause of Parkinson's disease. *Acta Neurologica Scandinavica*, **1991**, 136, 6-15	3.8	150
616	A review of the pharmacology of selegiline. *Acta Neurologica Scandinavica*, **1991**, 136, 44-59	3.8	87
615	Chemically induced Parkinson's disease. III: A study of a possible role of singlet molecular oxygen in Parkinson's disease. **1991**, 11, 261-7		3
614	Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. **1991**, 14, 213-26		145
613	Manganese neurotoxicity: cellular effects and blood-brain barrier transport. **1991**, 15, 333-40		221
612	Glutathione peroxidase in early and advanced Parkinson's disease. **1991**, 54, 679-82		31
611	Avicenna or Ibn Sina (980-1036 AD). **1991**, 54, 682		1

610	Parkinson's disease. **1992**, 68, 538-43		10
609	Induction of stress proteins in SV-40 transformed human RPE-derived cells by organic oxidants. **1992**, 11, 385-96		24
608	Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. *Neuroscience Letters*, **1992**, 142, 128-30	3.3	502
607	The mitochondrial electron transfer alteration as a factor involved in the brain aging. **1992**, 13, 361-8		109
606	Glutathione: new candidate neuropeptide in the central nervous system. *Neuroscience*, **1992**, 51, 835-42	3.9	55
605	Oxidative damage and cerebral aging. **1992**, 38, 601-9		65
604	Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices. **1992**, 59, 181-9		122
603	Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. **1992**, 13, 339-51		145
602	Serum lipid peroxides in patients with Parkinson's disease. *Neuroscience Letters*, **1992**, 136, 137-40	3.3	24
601	Characterization and localization of glutathione binding sites on cultured astrocytes. **1992**, 15, 207-15		23
600	Serum levels of vitamin A in Parkinson's disease. **1992**, 111, 73-6		15
599	Serum levels of zinc and copper in patients with Parkinson's disease. **1992**, 112, 30-3		38
598	Comparison of MPTP and amphetamines as dopaminergic neurotoxins. **1992**, 648, 87-95		13
597	Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. **1992**, 295, 132-6		65
596	Microsomal cytochrome P450 in human brain regions. **1992**, 44, 1223-5		28
595	What Process Causes Nigral Cell Death in Parkinson□ Disease?. **1992**, 10, 387-403		23
594	NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease. **1992**, 83, 636-46		64
593	Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embryonic brains. **1992**, 59, 118-27		47

592	The role of glutathione in aging and cancer. **1992**, 27, 615-26		58
591	Effects of exogenous factors on the cerebral glutathione in rodents. **1992**, 66, 279-85		10
590	Neurotoxicity of levodopa on catecholamine-rich neurons. *Movement Disorders*, **1992**, 7, 23-31	7	105
589	The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. **1992**, 32, 804-12		803
588	An introduction to the free radical hypothesis in Parkinson's disease. **1992**, 32 Suppl, S2-9		310
587	Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. **1992**, 32 Suppl, S82-7		402
586	Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. **1992**, 32 Suppl, S94-100		226
585	Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. **1992**, 32 Suppl, S105-10		80
584	Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage?. **1992**, 32 Suppl, S111-5		93
583	A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. *Movement Disorders*, **1993**, 8 Suppl 1, S1-7	7	30
582	Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. **1993**, 35, 67-82		96
581	Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry. **1993**, 614, 205-12		25
580	Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. **1993**, 18, 1101-6		25
579	Changes in heat shock protein 70 and ubiquitin mRNA levels in C1300 N2A mouse neuroblastoma cells following treatment with iron. **1993**, 60, 659-65		27
578	Increased striatal lipid peroxidation after intracerebroventricular MPP+ administration to mice. **1993**, 72, 364-8		53
577	A scientific rationale for protective therapy in Parkinson's disease. **1993**, 91, 161-80		26
576	Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. **1993**, 6, 45-52		29
575	Age and GSH metabolism in rat cerebral cortex, as related to oxidative and energy parameters. *Mechanisms of Ageing and Development*, **1993**, 70, 65-82	5.6	32

574	Thiazolidine derivatives as source of free L-cysteine in rat tissue. **1993**, 46, 1917-28		27
573	Serum levels of beta-carotene and other carotenoids in Parkinson's disease. *Neuroscience Letters*, **1993**, 157, 103-6	3.3	30
572	Glutathione peroxidase, glial cells and Parkinson's disease. *Neuroscience*, **1993**, 52, 1-6	3.9	363
571	Iron, melanin and dopamine interaction: relevance to Parkinson's disease. **1993**, 17, 139-50		34
570	Glutathione modulates the N-methyl-D-aspartate receptor-activated calcium influx into cultured rat cerebellar granule cells. *Neuroscience Letters*, **1993**, 156, 153-7	3.3	48
569	Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. **1993**, 118, 25-8		40
568	The lysosomal system in neuronal cell death: a review. **1993**, 679, 87-109		75
567	Free radicals and mitochondrial dysfunction in Parkinson's disease. **1993**, 21, 367-70		37
566	Mitochondrial dysfunction in neurodegenerative disorders and aging. **1994**, 227-244		12
565	Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. *Movement Disorders*, **1994**, 9, 92-7	7	367
564	Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. **1994**, 35, 298-303		47
563	The brain on fire?. **1994**, 36, 333-4		29
562	Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. **1994**, 36, 348-55		918
561	Glutathione-related enzymes in brain in Parkinson's disease. **1994**, 36, 356-61		271
560	Characterization of peroxidative oxidation products of dopamine by mass spectrometry. **1994**, 658, 21-30		8
559	Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. **1994**, 660, 8-18		143
558	Antisera to glutathione: characterization and immunocytochemical application to the rat cerebellum. **1994**, 6, 793-804		102
557	Peripheral iron metabolism in patients with Parkinson's disease. **1994**, 125, 82-6		26

556	Relationship between age and GSH metabolism in synaptosomes of rat cerebral cortex. **1994**, 15, 429-33		18
555	Localization of NADPH cytochrome P450 oxidoreductase in rat brain by immunohistochemistry and in situ hybridization and a comparison with the distribution of neuronal NADPH-diaphorase staining. *Neuroscience*, **1994**, 61, 331-50	3.9	47
554	Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. *Neuroscience Letters*, **1994**, 169, 126-8	3.3	172
553	Serum and urinary manganese levels in patients with Parkinson's disease. *Acta Neurologica Scandinavica*, **1995**, 91, 317-20	3.8	16
552	Decreased serum selenium concentrations in patients with Parkinson's disease. **1995**, 2, 111-4		12
551	Oxidative stress in Parkinson's disease. **1995**, 21, 3-9		76
550	The effect of deprenyl and levodopa on the progression of Parkinson's disease. **1995**, 38, 771-7		293
549	Melatonin protects neurons from singlet oxygen-induced apoptosis. **1995**, 18, 222-6		203
548	Influence of glutathione on the oxidation chemistry of the catecholaminergic neurotransmitter dopamine. **1995**, 398, 117-128		44
547	Neuronal antioxidant system and MPTP-induced oxidative stress in the striatum and brain stem of the rat. **1995**, 51, 581-92		15
546	Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. **1995**, 682, 133-43		118
545	An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. **1995**, 4, 271-81		77
544	Immunocytochemical evidence for the presence of high levels of reduced glutathione in radial glial cells and horizontal cells in the rabbit retina. *Neuroscience Letters*, **1995**, 193, 25-8	3.3	73
543	Vulnerability of mitochondrial complex I in PC12 cells exposed to manganese. **1995**, 293, 377-83		86
542	Oxygen radical detoxification processes during aging: the functional importance of melatonin. **1995**, 7, 340-51		34
541	Bioenergetic and oxidative stress in neurodegenerative diseases. **1995**, 56, 1151-71		258
540	Increased sensitivity to oxidative stress and the loss of muscarinic receptor responsiveness in senescence. **1996**, 786, 112-9		23
539	Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. *Neuroscience*, **1996**, 74, 39-50	3.9	115

538	Oxidative stress and antioxidant therapy in Parkinson's disease. **1996**, 48, 1-19		276
537	Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. **1996**, 35, 571-8		62
536	The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia. **1996**, 51, 983-6		29
535	Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. **1996**, 52, 1657-63		32
534	Quinolinic acid neurotoxicity: in vivo increased copper and manganese content in rat corpus striatum after quinolinate intrastriatal injection. **1996**, 87, 113-9		12
533	Reduced intravenous glutathione in the treatment of early Parkinson's disease. **1996**, 20, 1159-70		112
532	Relevance of Lewy bodies to alterations in oxidative stress in Lewy body dementia and Parkinson's disease. **1996**, 477-486		
531	Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. **1996**, 93, 1956-61		456
530	Evaluation of Free Radical-Initiated Oxidant Events within the Nervous System. **1996**, 243-259		4
529	Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. **1996**, 93, 2696-701		848
528	Glutamate and Parkinson's disease. *Molecular Neurobiology*, **1996**, 12, 73-94	6.2	258
527	Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. **1996**, 103, 315-29		19
526	Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. **1996**, 743, 278-83		148
525	Effect of ginsenoside Rb1 on lipid peroxidation and neurotoxicity induced by MPTP in liver and brain of mouse. **1996**, 28, 199-205		2
524	Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. **1996**, 144, 480-4		175
523	Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. *Journal of Neural Transmission Supplementum*, **1997**, 51, 167-73		39
522	Requirement for cGMP in nerve cell death caused by glutathione depletion. **1997**, 139, 1317-24		120
521	Levodopa-Induced Neurotoxicity. **1997**, 8, 376-393		46

520	Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. **1997**, 6, 309-15	33
519	Cerebrospinal fluid carnitine levels in patients with Parkinson's disease. **1997**, 145, 183-5	10
518	An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. **1997**, 148, 181-6	29
517	Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. **1997**, 53, 363-72	172
516	Expression of glutathione and gamma-glutamylcysteine synthetase mRNA is Jun dependent. **1997**, 234, 588-93	88
515	A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. **1997**, 19, 453-63	407
514	EPR investigations of the iron domain in neuromelanin. **1997**, 1361, 49-58	42
513	Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. **1997**, 1362, 77-86	209
512	Premorbid dietetic habits and risk for Parkinson's disease. **1997**, 3, 55-61	12
511	Species differences in the role of excitatory amino acids in experimental parkinsonism. **1997**, 21, 401-15	43
510	Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. **1997**, 25, 335-58	576
509	Comparison of Neurotoxicity following Repeated Administration of L-Dopa, D-Dopa, and Dopamine to Embryonic Mesencephalic Dopamine Neurons in Cultures Derived from Fisher 344 and Sprague-Dawley Donors. **1997**, 6, 309-315	45
508	In vitro and in vivo protective effects of melatonin against glutamate oxidative stress and neurotoxicity. **1997**, 825, 79-84	27
507	Neuroprotection by the metabolic antioxidant alpha-lipoic acid. **1997**, 22, 359-78	524
506	Cholesterol: a two-edged sword in brain aging. **1997**, 22, 455-62	32
505	Decreased glutathione results in calcium-mediated cell death in PC12. **1997**, 23, 1055-66	59
504	Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine. **1997**, 773, 76-81	17
503	Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro. **1997**, 777, 202-9	25

502	Metallothionein inducers protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. **1997**, 22, 17-22	24
501	Lesion of nigrostriatal neurons by 6-hydroxydopamine induces changes in rat brain glutathione-S-transferase. **1997**, 31, 149-59	6
500	Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration. **1997**, 58, 177-95	16
499	Mesencephalic neuron death induced by congeners of nitrogen monoxide is prevented by the lazaroid U-83836E. **1997**, 113, 138-43	24
498	Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. **1997**, 104, 67-75	78
497	Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. **1997**, 104, 649-60	87
496	Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. **1997**, 104, 661-77	273
495	Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. **1997**, 69, 1612-21	142
494	Stress, aging, and neurodegenerative disorders. Molecular mechanisms. **1998**, 851, 429-43	46
493	Expression of multiple forms of cytochrome P450 and associated mono-oxygenase activities in rat brain regions. **1998**, 56, 371-5	18
492	Some aspects of tyrosine secondary metabolism. **1998**, 56, 1089-96	18
491	Treatment with the spin-trap agent alpha-phenyl-N-tert-butyl nitrone does not enhance the survival of embryonic or adult dopamine neurons. **1998**, 805, 155-68	23
490	MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. **1998**, 24, 76-84	75
489	Striatal dopamine dynamics are altered following an intranigral infusion of iron in adult rats. **1998**, 24, 988-93	14
488	Cellular mechanisms of resistance to chronic oxidative stress. **1998**, 24, 1375-89	128
487	(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. **1998**, 25, 169-74	164
486	Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. **1998**, 54, 691-7	141
485	Subcellular compartmentation of glutathione and glutathione precursors. A high resolution immunogold analysis of the outer retina of guinea pig. **1998**, 198, 277-87	35

484	Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease. **1998**, 105, 1245-51		35
483	Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. **1998**, 14, 195-205		62
482	Direct evidence for glutathione as mediator of apoptosis in neuronal cells. **1998**, 52, 349-55		26
481	Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. *Journal of Biological Chemistry*, **1998**, 273, 12753-7	5.4	276
480	Understanding cell death in Parkinson's disease. **1998**, 44, S72-84		530
479	Manganese augments nitric oxide synthesis in murine astrocytes: a new pathogenetic mechanism in manganism?. **1998**, 149, 277-83		67
478	Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. **1998**, 150, 60-8		233
477	Repin-induced neurotoxicity in rodents. **1998**, 152, 129-36		18
476	Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. **1998**, 158, 24-9		127
475	The glutathione content of retinal Müller (glial) cells: the effects of aging and of application of free-radical scavengers. **1998**, 30, 351-60		31
474	Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death. **1998**, 95, 7748-53		93
473	Neurodegeneration and glutamate induced oxidative stress. **1998**, 116, 245-63		21
472	Peroxynitrite modulates tyrosine phosphorylation and phosphoinositide signalling in human neuroblastoma SH-SY5Y cells: attenuated effects in human 1321N1 astrocytoma cells. **1998**, 331 (Pt 2), 599-606		108
471	New directions in Parkinson research and treatment. **1998**, 8, 1251-1268		3
470	Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. **1998**, 12, 905-12		199
469	Excitotoxicity and oxidative stress during inhibition of energy metabolism. **1998**, 20, 444-53		46
468	Pathogenesis and preclinical course of Parkinson's disease. *Journal of Neural Transmission Supplementum*, **1999**, 56, 31-74		31
467	Mechanism and consequences of nerve cell death in Parkinson's disease. *Journal of Neural Transmission Supplementum*, **1999**, 56, 127-37		27

466	Final common pathways in neurodegenerative diseases: regulatory role of the glutathione cycle. **1999**, 23, 1079-86	52
465	Increased glutathione levels in neurochemically identified fibre systems in the aged rat lumbar motor nuclei. **1999**, 11, 2935-48	11
464	The antioxidative effect of carboxyfullerenes (C3/D3) on iron-induced oxidative injury in CNS. **1999**, 890, 340-51	4
463	Effect of vitamin E deficiency on rat brain monoamine metabolism. **1999**, 24, 1307-11	15
462	Parkinson's disease: a major hypokinetic basal ganglia disorder. **1999**, 106, 443-76	65
461	Immunocytochemical demonstration of reduced glutathione in neurons of rat forebrain. **1999**, 817, 199-205	10
460	Protection of methamphetamine nigrostriatal toxicity by dietary selenium. **1999**, 851, 76-86	84
459	Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate. **1999**, 27, 997-1007	16
458	Cytotoxic and genotoxic potential of dopamine. **1999**, 55, 659-65	354
457	Brain □glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels. **1999**, 58, 436-441	48
456	Does levodopa accelerate Parkinson's disease?. **1999**, 14, 399-408	20
455	The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. **1999**, 14, 115-40	171
454	Measurement of glutathione, glutathione disulfide, and other thiols in mammalian cell and tissue homogenates using high-performance liquid chromatography separation of N-(1-pyrenyl)maleimide derivatives. **1999**, 299, 258-67	41
453	Multiple antioxidants in the prevention and treatment of Parkinson's disease. **1999**, 18, 413-23	71
452	In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. **1999**, 1453, 407-11	39
451	An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. **1999**, 29, 1-25	315
450	Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease?. **1999**, 64, 1253-7	49
449	Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. **1999**, 38, 567-77	73

448	Reduced levels of catalase activity potentiate MPP+-induced toxicity: comparison between MN9D cells and CHO cells. **1999**, 104, 49-56	13
447	New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6, 7-dihydroxytetrahydroisoquinoline. **1999**, 12, 1090-7	52
446	Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. **1999**, 154, 1423-9	499
445	Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. **1999**, 159, 98-104	41
444	Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury. **1999**, 160, 376-85	30
443	L-DOPA-induced neurotoxic and apoptotic changes on cultured chromaffin cells. **2000**, 11, 503-6	14
442	Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease. **2000**, 74, 970-8	26
441	Glutathione, oxidative stress and neurodegeneration. **2000**, 267, 4904-11	886
440	Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease. **2000**, 914, 275-83	21
439	Melatonin suppresses iron-induced neurodegeneration in rat brain. **2000**, 28, 904-11	62
438	Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system. **2000**, 873, 203-11	14
437	In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. **2000**, 852, 221-4	51
436	Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g). **2000**, 853, 310-6	8
435	Cerebral antioxidant status and free radical generation following glutathione depletion and subsequent recovery. **2000**, 209, 55-61	16
434	NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. **2000**, 25, 1315-41	228
433	Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease. **2000**, 14, 147-53	18
432	Glial cells and Parkinson's disease. **2000**, 247 Suppl 2, II58-62	43
431	Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. **2000**, 247 Suppl 2, II82-94	58

430	Sequestration of iron by Lewy bodies in Parkinson's disease. **2000**, 100, 111-4		192
429	Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain. **2000**, 14, 955-67		139
428	Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. **2000**, 14, 1202-14		138
427	Molecular mechanisms of oxidative stress in aging: free radicals, aging, antioxidants and disease. **2000**, 881-923		10
426	Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. *Journal of Biological Chemistry*, **2000**, 275, 26096-101	5.4	206
425	Influence of exercise-induced oxidative stress on the central nervous system. **2000**, 713-751		4
424	The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. **2000**, 166, 235-45		84
423	Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. *Neuroscience*, **2000**, 101, 67-76	3.9	96
422	Oxidative stress during energy impairment in mesencephalic cultures is not a downstream consequence of a secondary excitotoxicity. *Neuroscience*, **2000**, 96, 309-16	3.9	23
421	Low selenium diet induces tyrosine hydroxylase enzyme in nigrostriatal system of the rat. **2000**, 84, 7-16		13
420	In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. **2000**, 36, 185-91		136
419	The early treatment of Parkinson's disease: levodopa, dopamine agonists or both. **2000**, 7, 27-33		7
418	Reactive oxygen species scavenging activity of Du-zhong (Eucommia ulmoides oliv.) and its active compounds. **2000**, 48, 3431-6		72
417	The biochemistry of aging. **2000**, 35, 1-62		141
416	Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. **2001**, 39, 141-9		155
415	Effect of acute administration of 1,2,3,4-tetrahydroisoquinoline on the levels of glutathione and reactive oxygen species, and on the enzymatic activity of gamma-glutamyl transpeptidase in dopaminergic structures of rat brain. *Neuroscience*, **2001**, 108, 413-20	3.9	10
414	Modulation of large conductance calcium-activated potassium channels from rat hippocampal neurons by glutathione. *Neuroscience Letters*, **2001**, 298, 115-8	3.3	16
413	Hypothyroidism in the developing rat brain is associated with marked oxidative stress and aberrant intraneuronal accumulation of neurofilaments. **2001**, 40, 273-9		55

412	Quantitation of reduced and total glutathione at the femtomole level by high-performance liquid chromatography with fluorescence detection: application to red blood cells and cultured fibroblasts. **2001**, 752, 123-32		132
411	Effects of glutathione depletion by 2-cyclohexen-1-one on excitatory amino acids-induced enhancement of activator protein-1 DNA binding in murine hippocampus. **2001**, 76, 1905-15		9
410	Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures. **2001**, 77, 1496-507		27
409	Carboxyfullerene prevents iron-induced oxidative stress in rat brain. **1999**, 72, 1634-40		110
408	Glutamyl cysteine synthetase catalytic and regulatory subunits localize to dopaminergic nigral neurons as well as to astrocytes. **2001**, 64, 203-6		6
407	6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. **2001**, 21, 771-81		47
406	Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. **2001**, 26, 739-64		209
405	Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease?. *Mechanisms of Ageing and Development*, **2001**, 122, 1499-510	5.6	46
404	SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. **2001**, 892, 241-7		33
403	6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. **2001**, 922, 51-64		28
402	Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats. **2001**, 30, 225-31		21
401	Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants. **2001**, 31, 986-98		28
400	Regulation of antioxidant metabolism by translation initiation factor 2alpha. **2001**, 152, 997-1006		60
399	Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. **2001**, 15, 1607-9		21
398	Chemistry and biochemistry of oxidative stress in neurodegenerative disease. **2001**, 8, 721-38		525
397	Iron and Parkinson's disease. **2002**, 8, 22-32		66
396	Parkinson's disease. **2002**, 53, 283-314		6
395	Oxidative stress involves in astrocytic alterations induced by manganese. **2002**, 175, 216-25		110

394	Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain. **2002**, 176, 328-35		42
393	Dopamine in the CNS II. *Handbook of Experimental Pharmacology*, **2002**,	3.2	1
392	Thiolic antioxidants protect from nitric oxide-induced toxicity in fetal midbrain cultures. **2002**, 43, 877-88		35
391	Glutathione depletion and oxidative stress. **2002**, 8, 385-7		142
390	A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. **2002**, 23, 719-35		254
389	Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection. *Neuroscience*, **2002**, 114, 361-72	3.9	19
388	PARKINSON'S DISEASE. **2002**, 927-960		
387	Interleukin-6 protects PC12 cells from 4-hydroxynonenal-induced cytotoxicity by increasing intracellular glutathione levels. **2002**, 32, 1324-32		41
386	Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. **2002**, 23, 57-63		54
385	Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease?. **2002**, 80, 555-61		60
384	Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. **2000**, 74, 2296-304		116
383	Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin. **2000**, 74, 2305-14		36
382	Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. **2001**, 79, 1183-95		54
381	5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. **2002**, 81, 122-9		92
380	Lazaroid treatment prevents death of cultured rat embryonic mesencephalic neurons following glutathione depletion. **1996**, 67, 1653-60		34
379	Oxidant injury in PC12 cells--a possible model of calcium "dysregulation" in aging: I. Selectivity of protection against oxidative stress. **1997**, 69, 1252-8		32
378	Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism. **1998**, 70, 1421-30		66
377	Role of endogenous glutathione in the oxidation of dopamine. **1998**, 71, 2071-8		66

376	Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. **1999**, 73, 112-9		38
375	Effect of MPTP on Dopamine metabolism in Ames dwarf mice. **2002**, 27, 457-64		8
374	Parkinson's Disease: Mechanisms of Neuronal Death. **2003**, 35, 54-66		2
373	Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease. **2003**, 5, 307-13		34
372	Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease. **2003**, 968, 206-18		29
371	Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. **2003**, 984, 224-32		81
370	Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. *Movement Disorders*, **2003**, 18, 969-76	7	64
369	Oxidative stress in Parkinson's disease. **2003**, 53 Suppl 3, S26-36; discussion S36-8		1488
368	Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. **2003**, 84, 438-46		114
367	Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. **2003**, 85, 645-50		80
366	Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. **2003**, 86, 1487-97		22
365	Selective and persistent activation of extracellular signal-regulated protein kinase by nitric oxide in glial cells induces neuronal degeneration in glutathione-depleted midbrain cultures. **2003**, 24, 1012-26		39
364	Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. **2003**, 26, 143-51		21
363	Nicotine protects rat brain mitochondria against experimental injuries. **2003**, 44, 642-52		73
362	Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. *Neuroscience Letters*, **2003**, 336, 105-8	3.3	81
361	Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease. **2003**, 110, 76-84		84
360	Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. **2003**, 37, 899-909		535
359	Disease model: Parkinson's disease. **2003**, 9, 360-5		135

358	Essentials of Apoptosis. **2003**,		3
357	Withania somnifera (Ashwagandha) attenuates antioxidant defense in aged spinal cord and inhibits copper induced lipid peroxidation and protein oxidative modifications. **2003**, 19, 211-22		44
356	Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. **2003**, 100, 4281-6		221
355	Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase. *Journal of Biological Chemistry*, **2003**, 278, 21542-9	5.4	77
354	Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system. **2003**, 37, 1003-12		5
353	Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. **2003**, 304, 792-800		67
352	Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. **2003**, 17, 717-9		69
351	Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease. **2003**, 37, 1131-6		33
350	Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. **2004**, 19, 280-6		16
349	Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. **2004**, 91, 667-82		84
348	Oxidative stress in neurodegeneration: cause or consequence?. **2004**, 10 Suppl, S18-25		1337
347	Brain antioxidant systems in human methamphetamine users. **2004**, 89, 1396-408		65
346	Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. **2004**, 90, 1076-84		66
345	Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells. **2004**, 37, 953-60		44
344	Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. **2004**, 24, 387-400		46
343	Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. **2004**, 36, 381-6		196
342	Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. **2004**, 29, 569-77		144
341	Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons. **2004**, 29, 1223-34		12

340	Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. **2004**, 111, 1237-51		50
339	Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. **2004**, 36, 25-32		98
338	Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. **2004**, 76, 551-62		35
337	A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. *Movement Disorders*, **2004**, 19, 687-92	7	237
336	Minocycline in Huntington's disease: a pilot study. *Movement Disorders*, **2004**, 19, 692-5	7	91
335	Levodopa in the treatment of Parkinson's disease: current controversies. *Movement Disorders*, **2004** , 19, 997-1005	7	291
334	Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. **2004**, 223, 161-6		116
333	Effects of red algae cultivated with deep-sea water on the oxidation□eduction status of liver, lung, brain, and bone metabolism in SAMP1 and SAMR1. **2004**, 1260, 413-416		3
332	Iron dysregulation and Parkinson's disease. **2004**, 6, S47-52		47
331	Melatonin generates singlet oxygen on laser irradiation but acts as a quencher when irradiated by lamp photolysis. **2005**, 38, 153-6		7
330	Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease. **2005**, 70, 1371-81		49
329	Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. **2005**, 1049, 147-55		102
328	Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. *Movement Disorders*, **2005**, 20, 271-82	7	64
327	Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka. **2005**, 112, 1177-99		8
326	Nitric Oxide and Dopamine Neurons. Implications for Parkinsons Disease. **2005**, 5, 193-205		1
325	Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons. *Journal of Biological Chemistry*, **2005**, 280, 38992-9001	5.4	62
324	Rapid purification and mass spectrometric characterization of mitochondrial NADH dehydrogenase (Complex I) from rodent brain and a dopaminergic neuronal cell line. **2005**, 4, 84-96		44
323	Evidence of oxidative stress in the neocortex in incidental Lewy body disease. **2005**, 64, 816-30		176

322	Parkinson's disease: the first common neurological disease due to auto-intoxication?. **2005**, 98, 215-26		37
321	Thiol redox state and oxidative stress in midbrain and striatum of weaver mutant mice, a genetic model of nigrostriatal dopamine deficiency. *Neuroscience Letters*, **2005**, 376, 24-8	3.3	17
320	Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease. **2005**, 64, 736-41		7
319	Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells. **2005**, 67, 466-75		29
318	Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. **2005**, 26, 587-95		104
317	Brain oxidation is an initial process in sleep induction. *Neuroscience*, **2005**, 130, 1029-40	3.9	57
316	Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H2O2-induced neuronal death. **2005**, 20, 141-54		57
315	Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: relevance to brain aging, neurodegenerative disorders, and longevity. **2006**, 8, 444-77		102
314	The role of oxidative stress in signal transduction changes and cell loss in senescence. **1994**, 738, 37-43		14
313	Superoxide dismutase expression in Parkinson's disease. **1994**, 738, 116-20		26
312	Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation. **1994**, 738, 392-9		91
311	Serotonin binding proteins: an in vitro model system for monoamine-related neurotoxicity. **1994**, 738, 408-18		1
310	In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. *Neuroscience Letters*, **2006**, 402, 137-41	3.3	38
309	Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity. **2006**, 51, 327-40		18
308	. **2006**,		31
307	The Role of Iron in the Pathogenesis of Parkinson's Disease. **2006**, 125-149		9
306	Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. **2002**, 965, 274-80		28
305	Lack of protective effect by intermittent hypoxia on MPTP-induced neurotoxicity in mice. **2001**, 939, 33-44		1

304	Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. **2006**, 41, 1442-8		103
303	Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. **2006**, 535, 199-207		22
302	Phosphoproteomic profiling of human SH-SY5Y neuroblastoma cells during response to 6-hydroxydopamine-induced oxidative stress. **2006**, 1763, 977-89		23
301	Oxidative Damage to Proteins: Structural Modifications and Consequences in Cell Function. **2006**, 399-471		12
300	Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. **2006**, 12, 3521-33		193
299	Overstimulation of PrPC signaling pathways by prion peptide 106-126 causes oxidative injury of bioaminergic neuronal cells. *Journal of Biological Chemistry*, **2006**, 281, 28470-9	5.4	58
298	Beating a dead horse: dopamine and Parkinson disease. **2007**, 69, 1701-11		101
297	An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. **2007**, 27, 4326-33		81
296	Peripheral blood markers of oxidative stress in Parkinson's disease. **2007**, 58, 78-83		66
295	Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. **2007**, 80, 1906-14		21
294	Upregulation of cerebral cortical glutathione synthesis by ammonia in vivo and in cultured glial cells: the role of cystine uptake. **2007**, 50, 883-9		22
293	Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem. **2007**, 9, 1591-603		60
292	Mitochondria in the etiology of Parkinson's disease. **2007**, 83, 479-91		7
291	Levodopa. **2007**, 84, 31-72		2
290	Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. **2007**, 27, 8138-48		298
289	Prevention and Therapy of Neurodegenerative Disorders: Role of Nutritional Antioxidants. **2007**, 621-661		8
288	Glutathione depletion in hippocampal cells increases levels of H and L ferritin and glutathione S-transferase mRNAs. **2007**, 12, 561-7		16
287	In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. **2007**, 101, 709-17		46

286	17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult. **2007**, 1164, 24-31		27
285	Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. **2007**, 1185, 8-17		39
284	Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. **2007**, 25, 401-11		172
283	Modulation of [3H]dopamine release by glutathione in mouse striatal slices. **2007**, 32, 1357-64		27
282	Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. **1994**, 62, 134-46		114
281	Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity. **2008**, 22, 6-11		55
280	The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. *Movement Disorders*, **2008**, 23 Suppl 3, S515-20	7	41
279	Myoglobin modification by enzyme-generated dopamine reactive species. **2008**, 14, 8661-73		21
278	Protective effects of a new metalloporphyrin on paraquat-induced oxidative stress and apoptosis in N27 cells. **2008**, 40, 125-32		8
277	Redox-based endoplasmic reticulum dysfunction in neurological diseases. **2008**, 107, 20-34		39
276	Oxidative and nitrative protein modifications in Parkinson's disease. **2008**, 44, 1787-94		153
275	Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide. **2008**, 1197, 159-69		50
274	Proteome analysis of human substantia nigra in Parkinson's disease. **2008**, 6, 8		115
273	Complex I and energy thresholds in the brain. **2008**, 1777, 777-82		32
272	The interplay between nitric oxide and peroxiredoxins. **2008**, 213, 815-22		22
271	Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. **2008**, 29, 408-17		61
270	Glutathione and Parkinson's disease: is this the elephant in the room?. **2008**, 62, 236-49		156
269	Redox imbalance in Parkinson's disease. **2008**, 1780, 1362-7		204

268	Oxygen-induced radical intermediates in the nNOS oxygenase domain regulated by L-arginine, tetrahydrobiopterin, and thiol. **2008**, 47, 405-20	24
267	Do Alterations in Glutathione and Iron Levels Contribute to Pathology Associated with Parkinson's Disease?. **2008**, 11-25	9
266	The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. **2009**, 11, 2105-18	125
265	A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. **2009**, 11, 2083-94	65
264	Does tissue glutathione level indicate organ senescence?. **1989**, 47, 330-2	3
263	Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. **2009**, 46, 593-8	41
262	Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. **2009**, 87, 1002-13	41
261	Levodopa in the treatment of Parkinson's disease. **2009**, 16, 982-9	136
260	Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. **2009**, 11, 509-28	77
259	The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. **2009**, 13, 319-29	103
258	Determination and applications of the molar absorptivity of phenolic adducts with captopril and mesna. **2009**, 57, 1143-50	
257	Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. **2009**, 88, 89-103	80
256	Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. **2009**, 125, 369-73	95
255	Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. **2009**, 30, 1030-5	20
254	Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. **2009**, 175, 54-65	73
253	Functional aspects of redox control during neuroinflammation. **2010**, 13, 193-247	49
252	Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. **2010**, 35, 1575-87	30
251	Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease. **2010**, 35, 1620-7	20

250	Fibroblast growth factor 9 upregulates heme oxygenase-1 and gamma-glutamylcysteine synthetase expression to protect neurons from 1-methyl-4-phenylpyridinium toxicity. **2010**, 49, 1099-108		28
249	Arsenite induces oxidative injury in rat brain: synergistic effect of iron. **2010**, 1199, 27-35		10
248	Persistent mitochondrial damage by nitric oxide and its derivatives: neuropathological implications. **2010**, 2, 1		75
247	Specific oxidative stress profile associated with partial striatal dopaminergic depletion by 6-hydroxydopamine as assessed by a novel multifunctional marker molecule. **2010**, 44, 635-44		15
246	Redox control of endoplasmic reticulum function. **2010**, 13, 77-108		70
245	Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease. **2010**, 49, 2715-24		53
244	Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. **2010**, 13, 919-49		69
243	Ageing and neurodegenerative diseases. **2010**, 9 Suppl 1, S36-46		137
242	Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease. **2011**, 45, 888-905		90
241	Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of □ipoic acid against rotenone-induced parkinsonism and L-dopa toxicity. **2011**, 71, 387-95		31
240	Comparison of HPLC and enzymatic recycling assays for the measurement of oxidized glutathione in rat brain. **1997**, 49, 332-5		19
239	The promise of neuroprotective agents in Parkinson's disease. **2011**, 2, 68		68
238	Oxidation of DJ-1 induced by 6-hydroxydopamine decreasing intracellular glutathione. *PLoS ONE*, **2011**, 6, e27883	3.7	29
237	□glutamylcysteine ethyl ester protects cerebral endothelial cells during injury and decreases blood-brain barrier permeability after experimental brain trauma. **2011**, 118, 248-55		15
236	Depletion of glutathione does not affect electron transport chain complex activity in brain mitochondria: Implications for Parkinson disease and postmortem studies. **2011**, 50, 899-902		12
235	What genetics tells us about the causes and mechanisms of Parkinson's disease. **2011**, 91, 1161-218		422
234	Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. **2011**, 36, 1452-63		106
233	Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. **2011**, 121, 475-85		44

232	Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+). **2011**, 118, 421-31		14
231	The most cited works in Parkinson's disease. *Movement Disorders*, **2011**, 26, 380-90	7	43
230	Anti-ageing effects of protocatechuic acid from Alpinia on spleen and liver antioxidative system of senescent mice. **2011**, 29, 342-7		38
229	Studies on Experimental Models. **2011**,		
228	Current concepts on the etiology and pathogenesis of Parkinson disease. **2011**, 93-118		0
227	Quantitative mapping of reversible mitochondrial Complex I cysteine oxidation in a Parkinson disease mouse model. *Journal of Biological Chemistry*, **2011**, 286, 7601-8	5.4	47
226	Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. **2011**, 45, 53-8		72
225	Chelators in the treatment of iron accumulation in Parkinson's disease. **2012**, 2012, 983245		55
224	□Glutamylcysteine detoxifies reactive oxygen species by acting as glutathione peroxidase-1 cofactor. **2012**, 3, 718		90
223	Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants. **2012**,		6
222	Mitochondria: redox metabolism and dysfunction. **2012**, 2012, 896751		74
221	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. **2012**, 34, 669-76		47
220	Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse. **2012**, 53, 1791-806		75
219	Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson's disease. **2012**, 17, 11391-420		24
218	X-ray absorption spectroscopy at the sulfur K-edge: a new tool to investigate the biochemical mechanisms of neurodegeneration. **2012**, 3, 178-85		56
217	N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?. **2012**, 79, 8-12		28
216	Lonicera japonica THUNB. protects 6-hydroxydopamine-induced neurotoxicity by inhibiting activation of MAPKs, PI3K/Akt, and NF-□B in SH-SY5Y cells. **2012**, 50, 797-807		34
215	Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?. **2012**, 36, 617-24		10

214	Synthesis of catecholamine conjugates with nitrogen-centered bionucleophiles. **2012**, 44, 19-24		7
213	Mitochondrial Dysfunction in Neurodegenerative Disorders. **2012**,		2
212	Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured hippocampal pyramidal neurons. **2012**, 5, 11		51
211	Iron toxicity in neurodegeneration. **2012**, 25, 761-76		136
210	Mucuna pruriens seeds in treatment of Parkinson disease: pharmacological review. **2013**, 13, 165-174		20
209	Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. **2013**, 62, 186-201		60
208	Long-term effects of ionising radiation on the brain: cause for concern?. **2013**, 52, 5-16		33
207	Autophagy and Mitophagy in Cellular Damage Control. **2013**, 1, 19-23		131
206	Relationship Between Serum Level of Selenium and Metabolites Using 1HNMR-Based Metabonomics in Parkinson Disease. **2013**, 44, 721-734		5
205	Neuroprotective effects of ketoglutarate and ethyl pyruvate against motor dysfunction and oxidative changes caused by repeated 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure in mice. **2013**, 32, 747-58		14
204	HIBCH mutations can cause Leigh-like disease with combined deficiency of multiple mitochondrial respiratory chain enzymes and pyruvate dehydrogenase. **2013**, 8, 188		57
203	Safety survey of intranasal glutathione. **2013**, 19, 459-63		15
202	Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. **2013**, 19, 1539-605		464
201	Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease. **2013**, 91, 453-61		51
200	Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. **2013**, 51, 35-42		305
199	Glutathione deficiency in Gclm null mice results in complex I inhibition and dopamine depletion following paraquat administration. **2013**, 134, 366-73		18
198	Oxidative stress and neurodegenerative disorders. *International Journal of Molecular Sciences*, **2013**, 14, 24438-75	6.3	249
197	The role of oxidative stress in Parkinson's disease. **2013**, 3, 461-91		875

196	Autophagy: A Possible Defense Mechanism in Parkinson's Disease?. **2013**,		
195	Oxidative Changes and Possible Effects of Polymorphism of Antioxidant Enzymes in Neurodegenerative Disease. **2013**,		1
194	The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. *Frontiers in Pharmacology*, **2014**, 5, 38	5.6	141
193	Loss of UCHL1 promotes age-related degenerative changes in the enteric nervous system. **2014**, 6, 129		23
192	Oxidized DJ-1 as a possible biomarker of Parkinson's disease. **2014**, 54, 138-44		47
191	Rhythmic oscillations of the microRNA miR-96-5p play a neuroprotective role by indirectly regulating glutathione levels. **2014**, 5, 3823		55
190	6-Hydroxydopamine as Preclinical Model of Parkinson□ Disease. **2014**, 639-651		1
189	Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. **2014**, 724, 31-42		23
188	Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson's disease. **2014**, 35, 897-903		6
187	Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson's disease brain is region dependent. **2014**, 24, 584-98		57
186	Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model. **2014**, 65, 1-13		41
185	Sulfuretin inhibits 6-hydroxydopamine-induced neuronal cell death via reactive oxygen species-dependent mechanisms in human neuroblastoma SH-SY5Y cells. **2014**, 74, 53-64		26
184	Selenium and selenoprotein function in brain disorders. **2014**, 66, 229-39		101
183	Antioxidant gene therapy against neuronal cell death. **2014**, 142, 206-30		77
182	Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. **2014**, 35, 1111-5		129
181	Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. **2014**, 94, 909-50		1961
180	Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra. **2014**, 65, 69-81		36
179	Ophthalmological features of Parkinson disease. **2014**, 20, 2243-9		60

178 Mitochondria in Parkinson's Disease. **2015**, 339-358

177 Mass spectrometry based detection of glutathione with sensitivity for single-cell analysis. **2015**, 29, 681-9 30

176 . **2015**,

175 Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model. **2015**, 89, 567-80 23

174 The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. **2015**, 13, 68 148

173 Free Radicals and Oxidative Stress in Neurodegenerative Disorders. **2015**, 143-158

172 Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease. **2015**, 24, 1322-35 31

171 Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease. **2015**, 28, 302-18 15

170 Dietary modifications in Parkinson's disease: A neuroprotective intervention?. **2015**, 85, 1002-5 11

169 Transcriptional mutagenesis by 8-oxodG in -synuclein aggregation and the pathogenesis of Parkinson's disease. **2015**, 47, e179 17

168 Glutamate excitotoxicity in neurons triggers mitochondrial and endoplasmic reticulum accumulation of Parkin, and, in the presence of N-acetyl cysteine, mitophagy. **2015**, 74, 180-93 69

167 Parkinson's Disease: The Mitochondria-Iron Link. **2016**, 2016, 7049108 36

166 Glutathione as a Biomarker in Parkinson's Disease: Associations with Aging and Disease Severity. **2016**, 2016, 9409363 32

165 The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. **2016**, 2016, 8590578 248

164 Further structure-activity relationships study of substituted dithiolethiones as glutathione-inducing neuroprotective agents. **2016**, 10, 64 8

163 Thiol Oxidation by Diamide Leads to Dopaminergic Degeneration and Parkinsonism Phenotype in Mice: A Model for Parkinson's Disease. **2016**, 25, 252-67 4

162 Deciphering variability in the role of interleukin-1 in Parkinson's disease. **2016**, 27, 635-50 11

161 Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease. **2016**, 101, 48-55 46

160	Carotenoids and Neurobiological Health. **2016**, 12, 199-228		13
159	Simultaneous assessment of endogenous thiol compounds by LC-MS/MS. **2016**, 1029-1030, 213-221		22
158	Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients. **2016**, 6, 30793		23
157	The protective mechanism of docosahexaenoic acid in mouse model of Parkinson: The role of hemeoxygenase. **2016**, 101, 110-110		27
156	Central nervous system uptake of intranasal glutathione in Parkinson's disease. **2016**, 2, 16002		33
155	Complex I assembly into supercomplexes determines differential mitochondrial ROS production in neurons and astrocytes. **2016**, 113, 13063-13068		175
154	Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite. **2016**, 29, 1098-107		20
153	Do glutathione levels decline in aging human brain?. **2016**, 93, 110-7		26
152	Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress. **2016**, 19, 237-46		54
151	Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. **2016**, 13, 217-25		24
150	Oxidative Stress in Neurodegenerative Diseases. *Molecular Neurobiology*, **2016**, 53, 4094-4125	6.2	367
149	Mitochondrial mechanisms of redox cycling agents implicated in Parkinson's disease. **2016**, 123, 113-23		7
148	Mitochondrial Complex I Activity is Conditioned by Supercomplex I-IIIIV Assembly in Brain Cells: Relevance for Parkinson's Disease. **2017**, 42, 1676-1682		13
147	Inhibition of neuronal mitochondrial complex I or lysosomal glucocerebrosidase is associated with increased dopamine and serotonin turnover. **2017**, 109, 94-100		6
146	Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease. **2017**, 326, 34-42		9
145	Mitochondrial respiratory chain disorganization in Parkinson's disease-relevant PINK1 and DJ1 mutants. **2017**, 109, 101-105		28
144	Maltodextrin modified liposomes for drug delivery through the blood-brain barrier. **2017**, 8, 1337-1345		23
143	Targeting urate to reduce oxidative stress in Parkinson disease. **2017**, 298, 210-224		67

142	Nutrition and Nonmotor Symptoms of Parkinson's Disease. **2017**, 134, 1143-1161		7
141	Post-Translational Oxidative Modifications of Mitochondrial Complex I (NADH: Ubiquinone Oxidoreductase): Implications for Pathogenesis and Therapeutics in Human Diseases. **2017**, 60, S69-S86		13
140	Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease. **2017**, 295, 77-87		50
139	Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson's disease and its relationship with clinical stage of disease. **2017**, 153, 50-55		16
138	DJ-1 as a Biomarker of Parkinson's Disease. *Advances in Experimental Medicine and Biology*, **2017**, 1037, 149-171	3.6	17
137	Alpha-synuclein-induced oxidative stress correlates with altered superoxide dismutase and glutathione synthesis in human neuroblastoma SH-SY5Y cells. **2017**, 91, 1245-1259		25
136	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. **2017**, 7, 289-299		38
135	Glaucoma in Patients with Parkinson Disease. **2017**, 07,		0
134	Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated Gene Mutations. **2017**, 9, 89		23
133	Protective effect of tangeritin in transgenic Drosophila model of Parkinson's disease. **2017**, 9, 44-53		14
132	Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. **2018**, 135, 62-74		46
131	Pannexin hemichannels: A novel promising therapy target for oxidative stress related diseases. **2018**, 233, 2075-2090		16
130	Sulforaphane Promotes Mitochondrial Protection in SH-SY5Y Cells Exposed to Hydrogen Peroxide by an Nrf2-Dependent Mechanism. *Molecular Neurobiology*, **2018**, 55, 4777-4787	6.2	29
129	Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. **2018**, 25, 2198-2214		69
128	Role of NADPH oxidase in cooperative reactive oxygen species generation in dopaminergic neurons induced by combined treatment with dieldrin and lindane. **2018**, 299, 47-55		12
127	Normal glutathione levels in autopsied brain of chronic users of heroin and of cocaine. **2018**, 190, 20-28		6
126	Disruption of the Circadian Clock Alters Antioxidative Defense via the SIRT1-BMAL1 Pathway in 6-OHDA-Induced Models of Parkinson's Disease. **2018**, 2018, 4854732		30
125	Treatment of Visual Disorders in Parkinson Disease. **2018**, 20, 30		3

124	What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?. **2019**, 9, 467-488		5
123	Phenotypic assays in yeast and zebrafish reveal drugs that rescue deficiency. **2019**, 1, fcz019		5
122	Disubstituted Dithiolethione ACDT Exerts Neuroprotective Effects Against 6-Hydroxydopamine-Induced Oxidative Stress in SH-SY5Y Cells. **2019**, 44, 1878-1892		5
121	Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification. **2019**, 199, 110717		25
120	Case report and novel treatment of an autosomal recessive Leigh syndrome caused by short-chain enoyl-CoA hydratase deficiency. **2019**, 179, 803-807		8
119	Preventing and Slowing the Progression of Parkinson's: A Clinical Conversation with Laurie Mischley, ND, MPH, PhD, and Robert Rountree, MD. **2019**, 25, 59-67		
118	Pharmacological strategies to lower crosstalk between nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mitochondria. **2019**, 111, 1478-1498		22
117	Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. **2019**, 30, 1450-1499		50
116	A dual druggable genome-wide siRNA and compound library screening approach identifies modulators of parkin recruitment to mitochondria. *Journal of Biological Chemistry*, **2020**, 295, 3285-3300	5.4	3
115	Fibrillar □synuclein toxicity depends on functional lysosomes. *Journal of Biological Chemistry*, **2020**, 295, 17497-17513	5.4	14
114	□Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. **2020**, 37, 101695		12
113	Co-administration of TiO-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury. **2020**, 258, 101-155		8
112	Index. **2020**, 160-162		
111	Common aspects between glaucoma and brain neurodegeneration. **2020**, 786, 108323		3
110	Evidence of a Role for the TRPC Subfamily in Mediating Oxidative Stress in Parkinson's Disease. **2020**, 11, 332		2
109	Nutraceuticals Targeting Generation and Oxidant Activity of Peroxynitrite May Aid Prevention and Control of Parkinson's Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	10
108	Healthspan Enhancement by Olive Polyphenols in Wild Type and Parkinson's Models. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	56
107	The Hypothesis That Refuses to Die. **2020**, 95-104		

106 Preface 1 The Question. **2020**, ix-x

105 The Shaky Six and the Second Reality **2020**, 1-10

104 Pieces of a Puzzle?. **2020**, 11-24

103 Disease Redefinition A Tough Pill to Swallow. **2020**, 25-32

102 Disease Subtypes: The Promise and the Fallacy. **2020**, 33-40

101 Protein Paradox. **2020**, 41-56

100 The Fault in Our Models. **2020**, 57-70

99 Biomarkers: The Promise and the Fallacy. **2020**, 71-80

98 Lessons from Oncology. **2020**, 81-86

97 Symptomatic vs. Disease-Modifying Therapies. **2020**, 87-94 0

96 Our Living Dissonance. **2020**, 105-110

95 The Scientific and Lay Narratives. **2020**, 111-124

94 Challenges Viewed from Afar. **2020**, 125-132

93 The Moonshot: Population-Based Studies of Aging. **2020**, 133-138

92 Predictions for the 2020s and Beyond. **2020**, 139-147

91 Note Added at Press Time Reviving LOF. **2020**, 150-150

90 References. **2020**, 151-159

89 Epilogue. **2020**, 148-149

88	Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice. *Movement Disorders*, **2020**, 35, 1843-1853	7	2
87	Silver nanoclusters and carbon dots based light-addressable sensors for multichannel detections of dopamine and glutathione and its applications in probing of parkinson's diseases. *Talanta*, **2020**, 219, 121290	6.2	5
86	Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?. *Biomolecules*, **2020**, 10,	5.9	37
85	The Effect of Sulfur-Containing Compounds on the Quinoid Process of Adrenaline Autoxidation; Potential Neuroprotectors. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry*, **2020**, 14, 62-69	0.4	
84	Proteomic Complexity in Parkinson's Disease: A Redox Signaling Perspective of the Pathophysiology and Progression. *Neuroscience*, **2021**, 453, 287-300	3.9	3
83	Perspective: Low Risk of Parkinson's Disease in Quasi-Vegan Cultures May Reflect GCN2-Mediated Upregulation of Parkin. *Advances in Nutrition*, **2021**, 12, 355-362	10	7
82	Etiology and pathogenesis of Parkinson disease. **2021**, 121-163.e16		1
81	Coumarin-based fluorescent probe for the detection of glutathione and nitroreductase. *Tetrahedron*, **2021**, 82, 131890	2.4	2
80	Intersection between Redox Homeostasis and Autophagy: Valuable Insights into Neurodegeneration. *Antioxidants*, **2021**, 10,	7.1	7
79	The Effect of Oxidized Dopamine on the Structure and Molecular Chaperone Function of the Small Heat-Shock Proteins, Β-Crystallin and Hsp27. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
78	Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson's disease?. *Journal of Neuroimmunology*, **2021**, 354, 577545	3.5	3
77	A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1). *International Journal of Neuroscience*, **2021**, 1-10	2	2
76	Regulation of Tissue Inflammation by 12-Lipoxygenases. *Biomolecules*, **2021**, 11,	5.9	6
75	15 Glutathione in the Nervous System: Roles in Neural Function and Health and Implications for Neurological Disease. **2007**, 347-399		9
74	Aging and Oxidative Stress Response in the CNS. **2008**, 103-146		5
73	Parkinson Disease. **1999**, 459-475		7
72	The Current Clinical Picture Of Parkinson Disease. **1988**, 1-10		2
71	Hydrogen Peroxide Production in Dopamine Neurons: Implications for Understanding Parkinson Disease. **1988**, 119-126		10

70	Aging-Related Pathology in Human Neuroblastoma and Teratocarcinoma Cell Lines. **1987**, 453-473		4
69	Potential Roles of Accelerated Dopamine Oxidation, Altered Glutathione Metabolism, 5-S-Cysteinyl-Dopamine and its Oxidative Metabolites in the Pathogenesis of Parkinson Disease. **2000**, 181-209		1
68	Formation of Excess Reactive Oxygen Species within the Brain. **1992**, 255-272		3
67	Parkinson's disease and Alzheimer's disease: neurodegenerative disorders due to brain antioxidant system deficiency?. *Advances in Experimental Medicine and Biology*, **1990**, 264, 493-8	3.6	24
66	Mitochondrial Disturbances in Parkinson Disease. **1994**, 169-176		3
65	Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. *Advances in Experimental Medicine and Biology*, **1996**, 387, 97-106	3.6	71
64	Manganese Neurotoxicity and Oxidative Damage. **1997**, 77-93		23
63	Neurodegenerative Disease and Oxidative Stress: Insights from an Animal Model of Parkinsonism. **1996**, 37-46		2
62	MPTP. **1998**, 141-194		14
61	MAO-B Inhibitors in Neurological Disorders with Special Reference to Selegiline. *Milestones in Drug Therapy*, **1993**, 253-275		3
60	Oxidative stress, antioxidants, aging and disease. **1995**, 1-14		20
59	Selective modulation of brain antioxidant defense capacity by genetic or metabolic manipulations. **1994**, 173-192		1
58	The Role of Dopamine in the Control of Neurobiological Functions. *Basic and Clinical Aspects of Neuroscience*, **1989**, 1-17		5
57	Molecular and Cellular Events Regulating Dopamine Neuron Survival. *Handbook of Experimental Pharmacology*, **2002**, 321-386	3.2	4
56	Impaired iron homeostasis in Parkinson's disease. *Journal of Neural Transmission Supplementum*, **2000**, 37-58		30
55	Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. *Journal of Neural Transmission Supplementum*, **1997**, 49, 103-10		38
54	Neurochemical abnormalities in Alzheimer disease and Parkinson disease a comparative review. *Journal of Neural Transmission Supplementum*, **1997**, 145-159		10
53	Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson disease?. *Key Topics in Brain Research*, **1989**, 243-248		7

52	Oxidative stress: a role in the pathogenesis of Parkinson's disease. *Journal of Neural Transmission Supplementum*, **1990**, 29, 241-9		58
51	MR imaging of putamenal iron predicts response to dopaminergic therapy in parkinsonian patients. *New Vistas in Drug Research*, **1990**, 99-109		5
50	Senile dementia of Alzheimer type and Parkinson disease: neurochemical overlaps and specific differences. *New Vistas in Drug Research*, **1990**, 221-232		6
49	Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. **1996**, 23-45		7
48	Photoinactivation of B-type monoamine oxidase by a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite.. *Journal of Biological Chemistry*, **1985**, 260, 11899-11902	5.4	6
47	Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them. **2020**,		2
46	The hunt for a cure for Parkinson's disease. *Science of Aging Knowledge Environment: SAGE KE*, **2001**, 2001, re1		2
45	Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. *Journal of Clinical Investigation*, **1995**, 95, 2458-64	15.9	188
44	Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. *PLoS ONE*, **2010**, 5, e12333	3.7	80
43	[Effect of the sulfur-containing compounds on the quinoid process of adrenaline autoxidation; potential neuroprotectors]. *Biomeditsinskaya Khimiya*, **2019**, 65, 316-323	0.8	5
42	Proteomic identification of oxidative-stress-reporting biomarkers differentially secreted from human neuroblastoma SH-SY5Y cells. *Journal of Electrophoresis*, **2007**, 51, 21-26	0.8	3
41	Molecules for Neuroprotection and Regeneration in Animal Models of Parkinson Disease. **2000**, 187-207		
40	Generation of Neurotoxins by New Reaction Pathways of Dopamine under Oxidative Stress Conditions: Contributing Etiopathological Factors in Parkinson Disease. **2000**, 233-236		
39	References. **2000**,		
38	Iron Chelators and Therapeutic Uses. **2003**, 480-561		
37	Cell-Death Mechanisms in Neurodegenerative Diseases. **2003**, 211-224		
36	Role of Nutritional Antioxidants in the Prevention and Treatment of Neurodegenerative Disorders. *Nutrition and Disease Prevention*, **2006**, 129-178		
35	Parkinson Disease. **2009**,		

34	Intervention with Multiple Micronutrients Including Dietary and Endogenous Antioxidants for Healthy Aging. **2010**, 55-78		
33	Micronutrients in Healthy Aging. **2010**, 35-53		
32	Protection of Oxidant-Induced Neuronal Cells Injury by a Unique Cruciferous Nutraceutical. **2011**, 563-577		
31	Potential Therapies for Mitochondrial Dysfunction. **2012**, 215-230		
30	Two Faces of 1,2,3,4-Tetrahydroisoquinoline Mode of Action in the Mammalian Brain: Is It an Endogenous Neurotoxin or a Neuromodulator?. **2012**, 3-30		0
29	Iron Neurotoxicity in Parkinson Disease. **2014**, 789-818		0
28	Diabetes. **2014**, 115-146		
27	Oxygen Free Radicals and Radical Scavengers in Neurology. **1990**, 557-563		1
26	Aging and Electron Leakage Outside Mitochondrial Energy-Transducing Sequence. **1992**, 41-52		
25	Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. *Acta Neurologica Scandinavica*, **1993**, 87, 6-13	3.8	80
24	Neurotoxic Phenylalkylamines and Indolealkylamines. **1994**, 225-291		
23	Parkinson Disease. **1996**, 343-388		
22	Oxidative Stress with Emphasis on the Role of LAMMA in Parkinson Disease. **1997**, 277-294		
21	Neurotransporters at the Juncture of Drug Action: Role in Programmed Cell Death, and Toxicity of Abused MDMA. **1997**, 237-248		
20	Oxidative Stress in Parkinson Disease. *Neuroscience Intelligence Unit*, **1997**, 175-193		
19	Etiological Considerations. **1997**, 153-185		
18	Metallothionein in oxidative stress of Parkinson disease. **1999**, 341-349		
17	6Chapter Micronutrients for the Prevention of Diabetes and Improvement of the Standard Therapy. **2016**, 103-128		

16	Preface 2 Enter Patient. **2020**, xi-xii		
15	Possible Therapeutic Potential of Flavonoids and Phenolic Acids from Honey in Age-Related Neurodegenerative Diseases Via Targeting NAD+ Degradation. **2020**, 19-43		
14	Conditioning Against the Pathology of Parkinson's disease. *Conditioning Medicine*, **2018**, 1, 143-162	1.4	5
13	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson's Disease. *Frontiers in Pharmacology*, **2021**, 12, 757161	5.6	8
12	Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase.. *Antioxidants*, **2022**, 11,	7.1	1
11	POTENTIAL PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS BY OLIVE POLYPHENOLS AND HYDROX.. *Mechanisms of Ageing and Development*, **2022**, 111637	5.6	3
10	-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases.. *Antioxidants*, **2022**, 11,	7.1	3
9	Cellular and Molecular Events Leading to Paraquat-Induced Apoptosis: Mechanistic Insights into Parkinson's Disease Pathophysiology.. *Molecular Neurobiology*, **2022**, 1	6.2	1
8	Highly selective fluorescent detection platform based on isoquinoline Schiff base ligand monitors glutathione in biological systems. *Journal of Photochemistry and Photobiology A: Chemistry*, **2022**, 428, 113864	4.7	0
7	Parkinson's Disease and the Metal-Microbiome-Gut-Brain Axis: A Systems Toxicology Approach.. *Antioxidants*, **2021**, 11,	7.1	0
6	CHAPTER 8. Redox Signalling in Dopaminergic Cell Death and Survival. *Issues in Toxicology*, 210-254	0.3	
5	CHAPTER 13. Biomarkers of Oxidative Stress in Parkinson Disease. *Issues in Toxicology*, 423-446	0.3	
4	Novel inflammasome and oxidative modulators in Parkinson disease: A prospective study. *Neuroscience Letters*, **2022**, 786, 136768	3.3	0
3	Mechanism Action of Iron Regulatory Protein 1 (IRP1/ACO1) in Disease. **2022**, 12, 11662-11668		0
2	Increased cysteine metabolism in PINK1 models of Parkinson's disease. **2023**, 16,		0
1	Mitochondrial Complex I Inhibition in Dopaminergic Neurons Causes Altered Protein Profile and Protein Oxidation: Implications for Parkinson disease.		0